Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine in weight-loss functional dyspepsia with depressive symptoms
ChiCTR-IPR-15007460Phase 4Not yet recruiting
- Sponsor
- Guangzhou First Municipal People's Hospital, Guangzhou Nan Sha Center Hospital Affiliated to Guangzhou Medical University
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirtazapine and paroxetine in functional dyspepsia (FD) and major depressive disorder (MDD) (3 arms), sponsored by Guangzhou First Municipal People's Hospital, Guangzhou Nan Sha Center Hospital Affiliated to Guangzhou Medical University. Primary endpoints: Pepsinogen, Gastrin-17 and 1 more. Planned start Dec 2015; status: not yet recruiting.
02
Drugs
mirtazapineparoxetine
03
Conditions
functional dyspepsia (FD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR-IPR-15007460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007460.